HSBC Holdings
VKTX icon

HSBC Holdings’s Viking Therapeutics VKTX Stock Holding History

HSBC Holdings’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$646K Sell
15,751
-2,368
-13% -$76.5K ﹤0.01% 2161
2026
Q1 		$592K Buy
18,119
+5,772
+47% +$186K ﹤0.01% 2149
2025
Q4 		$436K Sell
12,347
-27,485
-69% -$974K ﹤0.01% 2378
2025
Q3 		$1.03M Buy
39,832
+5,856
+17% +$175K ﹤0.01% 1783
2025
Q2 		$906K Buy
33,976
+16,101
+90% +$424K ﹤0.01% 1852
2025
Q1 		$430K Buy
17,875
+12,026
+206% +$380K ﹤0.01% 2161
2024
Q4 		$233K Sell
5,849
-9,437
-62% -$538K ﹤0.01% 2630
2024
Q3 		$959K Buy
15,286
+1,540
+11% +$90.3K ﹤0.01% 1714
2024
Q2 		$738K Buy
13,746
+9,230
+204% +$605K ﹤0.01% 1801
2024
Q1 		$370K Buy
+4,516
New +$201K ﹤0.01% 2280
2020
Q2 		– Sell
-11,883
Closed -$56K – 2876
2020
Q1 		$56K Buy
+11,883
New +$73K ﹤0.01% 2547

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HSBC Holdings's VKTX Position: Q2 2026 in Review

HSBC Holdings reduced its Viking Therapeutics (VKTX) stake by 13% in Q2 2026, selling an estimated $76.5K and leaving 15,751 shares worth $646K. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

HSBC Holdings first reported a position in VKTX in Q1 2020 and has held it in 11 quarters since. The position peaked at $1.03M in Q3 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • HSBC Holdings held 15,751 shares of Viking Therapeutics worth $646K as of Q2 2026.
  • HSBC Holdings sold 2,368 Viking Therapeutics shares in Q2 2026, an estimated $76.5K.
  • Viking Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2161 holding.
  • HSBC Holdings first reported a position in Viking Therapeutics in Q1 2020 and has held it in 11 quarters since.
  • HSBC Holdings's Viking Therapeutics position peaked at $1.03M in Q3 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.